Applying Newer Biologic Therapies to Improve Outcomes in Patients with Moderate-to-Severe Psoriasis

http://academiccme.com/wp-content/uploads/2017/06/Psoriasis-Image-wpcf_400x400.jpg

Course Information

Therapautic Area: Dermatology
Format(s): Webcast
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: July 5, 2017 - July 4, 2018

 

Program Overview

This CME webcast was derived from a live symposium at the Florida Society of Dermatology and Dermatologic Surgery 2017 Annual Meeting held in Hollywood, Florida. The expert faculty, Richard Fried, MD, PhD, will explain the mechanisms of action of various emerged and emerging biologic therapies for the treatment of moderate-to-severe psoriasis. Recently released clinical trial data, as it relates to patient care, will be reviewed. Dr. Fried will also discuss how to engage all members of the interdisciplinary team to create optimal, personalized treatment plans for psoriasis patients. Upon completion of this educational activity, learners will have a better understanding of newer biologic therapies for the treatment of psoriasis and how to to utilize them to improve patient outcomes.

Target Audience

Dermatologists, primary care physicians, and other healthcare professionals who care for patients with psoriasis.

Learning Objectives

  1. Understand the science of current and emerging biologic therapies for the treatment of moderate-to-severe psoriasis.
  2. Examine clinical trial data for current and emerging biologic therapies for the treatment of moderate-to-severe psoriasis.
  3. Apply principles of personalized medicine to treatment plans for patients with moderate-to-severe psoriasis.

Faculty

Screen Shot 2017-06-28 at 2.57.38 PMRichard Fried, MD, PhD
Dermatologist/Clinical Psychologist
Clinical Director
Yardley Dermatology Associates
Yardley Clinical Research Associates
Yardley, Pennsylvania

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Richard Fried, MD, PhD Consultant/Advisor: Allergan; Galderma Laboratories L.P.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Sun Pharmaceutical Industries Ltd.Speaker’s Bureau: Eli Lilly and Company

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski and Megan Gentile hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by AcademicCME

AcademicCME Logo